Abstract:Macfarlane DP, Zou X, Andrew R, Morton NM, Livingstone DE, Aucott RL, Nyirenda MJ, Iredale JP, Walker BR. Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis. Am J Physiol Endocrinol Metab 300: E402-E409, 2011. First published November 30, 2010; doi: 10.1152/ajpendo.00331.2010.-The pathological mechanisms that distinguish simple steatosis from steatohepatitis (or NASH, with consequent risk of cirrhosis and hepatocellular cancer) remain incompletely defined. Whereas both a methionine-and choline-deficient diet (MCDD) and a choline-deficient diet (CDD) lead to hepatic triglyceride accumulation, MCDD alone is associated with hepatic insulin resistance and inflammation (steatohepatitis). We used metabolic tracer techniques, including stable isotope ([C-13(4)]palmitate) dilution and mass isotopomer distribution analysis (MIDA) of [C-13(2)] acetate, to define differences in intrahepatic fatty acid metabolism that could explain the contrasting effect of MCDD and CDD on NASH in C57Bl6 mice. Compared with control-supplemented (CS) diet, liver triglyceride pool sizes were similarly elevated in CDD and MCDD groups (24.37 +/- 2.4, 45.94 +/- 3.9, and 43.30 +/- 3.5 mu mol/liver for CS, CDD, and MCDD, respectively), but intrahepatic neutrophil infiltration and plasma alanine aminotransferase (31 +/- 3, 48 +/- 4, 231 +/- 79 U/l, P < 0.05) were elevated only in MCDD mice. However, despite loss of peripheral fat in MCDD mice, neither the rate of appearance of palmitate (27.2 +/- 3.5, 26.3 +/- 2.3, and 28.3 +/- 3.5 mu mol.kg(-1).min(-1)) nor the contribution of circulating fatty acids to the liver triglyceride pool differed between groups. Unlike CDD, MCDD had a defect in hepatic triglyceride export that was confirmed using intravenous tyloxapol (142 +/- 21, 122 +/- 15, and 80 +/- 7 mg.kg(-1).h(-1), P < 0.05). Moreover, hepatic de novo lipogenesis was significantly elevated in the MCDD group only (1.4 +/- 0.3, 2.3 +/- 0.4, and 3.4 +/- 0.4 mu mol/day, P < 0.01). These findings suggest that important alterations in hepatic fatty acid metabolism may promote the development of steatohepatitis. Similar mechanisms may predispose to hepatocyte damage in human NASH.

Deficient Chaperone‐Mediated Autophagy in Macrophage Aggravates Inflammation of Nonalcoholic Steatohepatitis by Targeting Nup85

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling

Increased CHCHD2 Expression Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis Via Notch/osteopontin Signaling.

The role of C5aR1-mediated hepatic macrophage efferocytosis in NASH

Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage PPARγ to prevent NASH progression in mice

Antagonizing circRNA_002581–miR-122–CPEB1 axis alleviates NASH through restoring PTEN–AMPK–mTOR pathway regulated autophagy

CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status

Macrophage-Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis

Circrna Expression Pattern And Circrna-Mirna-Mrna Network In The Pathogenesis Of Nonalcoholic Steatohepatitis

Deficient Chaperone-Mediated Autophagy Promotes Inflammation and Atherosclerosis

Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD

Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis.

Novel insights into macrophage immunometabolism in nonalcoholic steatohepatitis

Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH.

Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy

NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

The lack of PPARα exacerbated the progression of non-alcoholic steatohepatitis in mice with spleen deficiency syndrome by triggering an inflammatory response

Impaired Mitophagy Triggers NLRP3 Inflammasome Activation During the Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation